title: Clinicopathological Features and Therapeutic Responses of Chinese Patients with Advanced Lung Adenocarcinoma Harboring an Anaplastic Lymphoma Kinase Rearrangement.
abstract: Presence of anaplastic lymphoma kinase (ALK) rearrangement is an indication for crizotinib in the treatment of patients with advanced or metastatic lung adenocarcinoma. Here, we sought to elucidate the association between clinicopathological features and ALK rearrangement status in Chinese patients with advanced lung adenocarcinoma harboring an ALK rearrangement.
  
  
  
  ALK rearrangement status was determined using immunohistochemistry (IHC) in tumor tissues from 120 patients with advanced lung adenocarcinoma, and further assessed by fluorescence in situ hybridization (FISH) assay. The associations between ALK rearrangement status and clinicopathological features were analyzed.
  
  
  
  According to IHC testing, the ALK-positive rate among the advanced lung adenocarcinoma patients was 6.67% (8/120). FISH validation found 5 patients with ALK rearrangement among the 8 IHC-positive cases. No significant difference was observed regarding age, sex, or smoking status between FISH-positive and -negative patients (p > 0.05). None of the 5 FISH-positive patients benefited from first-line chemotherapy.
  
  
  
  IHC can be used as a reliable method for ALK rearrangement screening in patients with lung adenocarcinoma, but further FISH validation is imperative. Presence of ALK rearrangement predicts a more aggressive biological behavior of the tumor and might be indicative of poor response to chemotherapy.
authors.forename: Danxia
authors.initials: D
authors.lastname: Lin
authors.forename: De
authors.initials: D
authors.lastname: Zeng
authors.forename: Chen
authors.initials: C
authors.lastname: Chen
authors.forename: Xiao
authors.initials: X
authors.lastname: Wu
authors.forename: Miaojun
authors.initials: M
authors.lastname: Wang
authors.forename: Jiongyu
authors.initials: J
authors.lastname: Chen
authors.forename: Hui
authors.initials: H
authors.lastname: Lin
authors.forename: Xihui
authors.initials: X
authors.lastname: Qiu
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology*; D000328:Adult; D000368:Aged; D000077548:Anaplastic Lymphoma Kinase; D000971:Antineoplastic Combined Chemotherapy Protocols; D002681:China; D000077547:Crizotinib; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D011720:Pyrazoles / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics / Q000378:metabolism*; D012307:Risk Factors; D055815:Young Adult
chemical_list: D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases